Investors Purchase High Volume of Put Options on Insmed (NASDAQ:INSM)

Insmed Incorporated (NASDAQ:INSM) was the target of some unusual options trading activity on Monday. Traders bought 1,584 put options on the stock. This represents an increase of approximately 1,550% compared to the typical volume of 96 put options.

In other news, CAO John Goll sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $20.80, for a total value of $520,000.00. Insiders own 4.95% of the company’s stock.

Large investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its stake in Insmed by 12.6% in the second quarter. Vanguard Group Inc. now owns 7,979,937 shares of the biopharmaceutical company’s stock valued at $204,287,000 after buying an additional 896,047 shares during the last quarter. Vivo Capital LLC increased its holdings in shares of Insmed by 49.4% during the second quarter. Vivo Capital LLC now owns 1,748,174 shares of the biopharmaceutical company’s stock valued at $44,753,000 after acquiring an additional 577,884 shares in the last quarter. Eagle Asset Management Inc. raised its position in shares of Insmed by 1.5% in the 3rd quarter. Eagle Asset Management Inc. now owns 1,524,798 shares of the biopharmaceutical company’s stock valued at $26,897,000 after purchasing an additional 23,240 shares during the last quarter. Carillon Tower Advisers Inc. purchased a new position in shares of Insmed in the 2nd quarter valued at approximately $26,785,000. Finally, Emerald Advisers LLC boosted its stake in Insmed by 7.6% in the 3rd quarter. Emerald Advisers LLC now owns 984,987 shares of the biopharmaceutical company’s stock worth $17,375,000 after purchasing an additional 69,468 shares in the last quarter.

Several research analysts have recently commented on INSM shares. ValuEngine raised Insmed from a “hold” rating to a “buy” rating in a research report on Monday, November 25th. Credit Suisse Group reaffirmed a “buy” rating and set a $40.00 price objective on shares of Insmed in a research report on Tuesday, September 10th. Morgan Stanley set a $37.00 target price on Insmed and gave the company a “buy” rating in a research note on Friday, November 1st. BidaskClub upgraded shares of Insmed from a “sell” rating to a “hold” rating in a report on Monday, November 25th. Finally, HC Wainwright reissued a “buy” rating on shares of Insmed in a research report on Thursday, October 31st. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $35.88.

NASDAQ INSM opened at $22.97 on Wednesday. The firm’s fifty day simple moving average is $19.66 and its two-hundred day simple moving average is $20.69. The firm has a market capitalization of $2.05 billion, a P/E ratio of -5.51 and a beta of 3.04. The company has a current ratio of 6.97, a quick ratio of 6.70 and a debt-to-equity ratio of 1.19. Insmed has a 12-month low of $11.31 and a 12-month high of $33.13.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Wednesday, October 30th. The biopharmaceutical company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.01). The business had revenue of $38.89 million for the quarter, compared to analysts’ expectations of $35.89 million. Insmed had a negative net margin of 291.19% and a negative return on equity of 114.68%. During the same quarter in the prior year, the company posted ($1.14) EPS. As a group, sell-side analysts predict that Insmed will post -2.91 earnings per share for the current fiscal year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Recommended Story: Diluted Earnings Per Share

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.